Trent Thiede, PharmD, MBA | PAAS National

About Trent Thiede, PharmD, MBA

I started working at Shopko, a community pharmacy, in high school. Shopko was a regional chain, and I worked there for 15 years, holding positions as Pharmacy Manager and Regional Pharmacy Supervisor while completing my PharmD from UW-Madison and MBA from UW-Oshkosh. In 2013, I took over Shopko’s Long-Term Care division and helped divest it to KPH HealthCare (aka Kinney Drugs/HealthDirect). I helped grow their business throughout the Midwest, eventually servicing 20,000 beds in under four years.

I have always been involved in pharmacy audits, and hated recoupments, but didn’t see all the opportunities to combat audits the way PAAS does. PAAS is a small, family-orientated company, and I appreciate the opportunity to help independent pharmacies be more successful.

Entries by Trent Thiede, PharmD, MBA

Audit Risk: Ivermectin Used for Treating COVID-19 (September Update)

September 2, 2021

Dangers of using Ivermectin to treat or prevent COVID-19. PAAS is seeing more PBM audits on ivermectin prescriptions. Pharmacies should be prepared!

FDA Guidance on Insulin Pens Puzzling

January 1, 2021

On October 13, 2020, the U.S. Food and Drug Administration issued a statement looking to clarify the intent of the November 2019 label revisions for insulin pens.

Smartphones Put Pharmacies at Risk for Inappropriate PHI Disclosures

June 26, 2020

Smartphone utilization has, unfortunately, become pervasive with patient interactions. Patients on their phone while trying to consult on new medications, or a patient snapchatting a friend while waiting for their prescription to be filled is all too common.

COVID-19 Audit Considerations Follow-Up

June 26, 2020

On April 3, 2020, PAAS National^® sent an urgent email alert to all members discussing COVID-19 audit considerations. This email came as a result of our desire to help pharmacies on the frontlines of this pandemic.

Stop Breaking Insulin Pen Boxes

March 1, 2020